101 Therapeutics Releases Clinical Evidence Package for Macrophage-Targeted 101-PGC-005 and Seeks Urgent Independent Review for Bundibugyo Ebola Disease Phase II/III clinical data and Ebola white ...
NEW YORK, Nov. 20, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results